false 0000876378 0000876378 2022-02-02 2022-02-02
 


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 

 
FORM 8-K
 

 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
February 2, 2022
Date of Report (date of earliest event reported)
 

 
Asensus Surgical, Inc.
(Exact name of Registrant as specified in its charter)
 

 
Delaware
(State or other jurisdiction of
incorporation or organization)
 
0-19437
(Commission
File Number)
 
11-2962080
(I.R.S. Employer
Identification Number)
 
1 TW Alexander Drive, Suite 160
Durham, NC 27703
(Address of principal executive offices)
919-765-8400
(Registrants telephone number, including area code)
 
Not Applicable
(Former name or former address, if changed since last report)
 

 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading symbol
 
Name of each exchange on which registered
Common Stock
$0.001 par value per share
 
ASXC
 
NYSE American
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
     Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 


 
 

 
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On February 2, 2022, the independent members of the Board of Directors (the “Board”) of Asensus Surgical, Inc. (the “Company”), upon the recommendation of the Compensation Committee (the “Committee”) of the Board approved the 2021 incentive bonuses, retention bonuses and compensation changes for 2022 for Anthony Fernando, the CEO, and Shameze Rampertab, the CFO, of the Company.
 
As will be described in more detail in the Company’s proxy materials for its 2022 Annual Meeting of Stockholders to be held later this year, the 2021 incentive bonuses of $280,500 for Mr. Fernando and $138,125 for Mr. Rampertab, were based on achievement of pre-established corporate goals at an 85% achievement rate. No increase in base salary was approved for the CEO and CFO for 2022. The Board did approve long-term incentive compensation for 2022 in the form of equity awards as set forth below, consisting of a one-third mix each of stock options, time-based restricted stock units (with a three-year vesting schedule) and performance-based restricted stock units (with a three-year vesting that occurs only upon achievement of a designated corporate performance goal).
 
In addition, the Committee and the independent members of the Board approved a discretionary retention bonus consisting of cash and Restricted Stock Units (RSUs) with a one-year cliff vesting period for each of the CEO and CFO as set forth below.
 
These annual and discretionary retention awards were made after careful consideration of the extraordinary efforts of the executive officers, particularly Mr. Fernando, in leading the Company through the challenges of 2021, achieving success in the reaching the pre-established corporate goals at an 85% level of achievement despite such challenges, maintaining the Company’s focus on its strategic goals, and continuing to adapt to the significant impact of COVID‑19 on hospitals and surgeons, and on the Company’s business and strategic focus. The corporate goals were based on improvement in the number of procedures performed globally using the Company’s Senhance Surgical® robotic surgical system for laparoscopic general surgery procedures, publications regarding the Company’s products, continued success in filing and receiving regulatory clearance for the Company’s product offerings, all while meeting budgetary goals and preserving capital. The Committee and Board also considered the executive officers’ compensation as compared to the peer company executive compensation data for the Company’s peer group of companies in making these awards. Following these awards the executive officers collectively hold shares and equity awards equal to approximately 2.9% of outstanding shares.
 
2022 Equity Grants to Executive Officers
 
Executive Officer
 
Stock Options
   
RSUs
   
PRSUs
 
Anthony Fernando, President and Chief Executive Officer
    578,000       486,900       486,900  
Shameze Rampertab, EVP and Chief Financial Officer
    222,500       187,250       187,250  
 
2022 Discretionary Retention Bonus
 
Executive Officer
 
RSUs
   
Cash
 
Anthony Fernando, President and Chief Executive Officer
    280,899     $ 250,000  
Shameze Rampertab, EVP and Chief Financial Officer
      84,270     $   75,000  
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
ASENSUS SURGICAL, INC.
Date: February 7, 2022
By:
/s/ Shameze Rampertab
Shameze Rampertab
Executive Vice President and Chief
Financial Officer
 
 
 
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Déc 2022 à Jan 2023 Plus de graphiques de la Bourse Asensus Surgical
Asensus Surgical (AMEX:ASXC)
Graphique Historique de l'Action
De Jan 2022 à Jan 2023 Plus de graphiques de la Bourse Asensus Surgical